Harbin Medisan Pharmaceutical Co Ltd Net Asset Quality Index
Harbin Medisan Pharmaceutical Co Ltd net asset quality index. Harbin Medisan Pharmaceutical Co Ltd (002900) has a Net Asset Quality Index of 52.8% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.61 Billion minus total liabilities of CN¥1.70 Billion yields net assets of CN¥1.90 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check cash flow quality index of Harbin Medisan Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
Net asset quality index of Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024. This chart shows how Harbin Medisan Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2012 to 2024. As of September 2025, the index stands at 52.8%, representing net assets of CN¥1.90 Billion against total assets of CN¥3.61 Billion CNY. See net assets of Harbin Medisan Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Harbin Medisan Pharmaceutical Co Ltd Net Asset Quality Index by Year (2012–2024)
Harbin Medisan Pharmaceutical Co Ltd net asset quality index by year from 2012 to 2024. The table below presents the year-by-year Net Asset Quality Index for Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Harbin Medisan Pharmaceutical Co Ltd stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 56.9% | CN¥2.16 Billion | CN¥3.80 Billion | CN¥1.64 Billion | ▼ -5.4 pp |
| 2023 | 62.4% | CN¥2.15 Billion | CN¥3.44 Billion | CN¥1.29 Billion | ▼ -0.2 pp |
| 2022 | 62.6% | CN¥2.05 Billion | CN¥3.28 Billion | CN¥1.22 Billion | ▼ -6.4 pp |
| 2021 | 69.0% | CN¥2.12 Billion | CN¥3.07 Billion | CN¥949.04 Million | ▼ -3.1 pp |
| 2020 | 72.2% | CN¥1.79 Billion | CN¥2.48 Billion | CN¥691.18 Million | ▲ +2.9 pp |
| 2019 | 69.3% | CN¥1.85 Billion | CN¥2.67 Billion | CN¥820.44 Million | ▼ -9.1 pp |
| 2018 | 78.4% | CN¥1.97 Billion | CN¥2.51 Billion | CN¥543.78 Million | ▼ -5.7 pp |
| 2017 | 84.0% | CN¥1.83 Billion | CN¥2.18 Billion | CN¥348.80 Million | ▲ +14.7 pp |
| 2016 | 69.3% | CN¥808.17 Million | CN¥1.17 Billion | CN¥358.01 Million | ▲ +0.2 pp |
| 2015 | 69.1% | CN¥727.97 Million | CN¥1.05 Billion | CN¥324.95 Million | ▲ +6.4 pp |
| 2014 | 62.8% | CN¥609.16 Million | CN¥970.46 Million | CN¥361.30 Million | ▲ +20.2 pp |
| 2013 | 42.6% | CN¥365.13 Million | CN¥857.75 Million | CN¥492.63 Million | ▼ -5.1 pp |
| 2012 | 47.7% | CN¥342.72 Million | CN¥719.01 Million | CN¥376.29 Million | — |